SCHEMBL3250602

SCHEMBL3250602

CCOC(=O)c1c[nH]c2c(=O)[nH]c3ccc(S(=O)(=O)NC4CC4)cc3c12

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARG Q86W56 1/20 0.50
TDP1 Q9NUW8 2/20 0.46
POLB P06746 3/20 0.45
BRAF P15056 1/20 0.44
MAPT P10636 4/20 0.41
TP53 P04637 3/20 0.41
LMNA P02545 4/20 0.40
TSHR P16473 1/20 0.40
ALDH1A1 P00352 3/20 0.40
GABRA1 P14867 2/20 0.39
GABRB2 P47870 2/20 0.39
MEN1 O00255 1/20 0.39
HPGD P15428 1/20 0.39
ALOX15 P16050 1/20 0.39
MAPK1 P28482 1/20 0.39
KMT2A Q03164 1/20 0.39
HSD17B10 Q99714 1/20 0.39
THRB P10828 1/20 0.39
GABRB1 P18505 1/20 0.39
GABRA3 P34903 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3247256 0.96 TDP1 (0.53) PARGTDP1POLBMAPTTP53
SCHEMBL3250480 0.96 TDP1 (0.53) PARGTDP1POLBMAPTTP53
SCHEMBL3254905 0.95 PARG (0.45) PARGTDP1POLBBRAFMAPT
SCHEMBL3254810 0.93 PARG (0.48) PARGTDP1POLBBRAFMAPT
SCHEMBL3248891 0.92 PARG (0.41) PARGTDP1POLBBRAFMAPT
SCHEMBL3250747 0.88 PARG (0.43) PARGTDP1POLBBRAFMAPT
SCHEMBL3248963 0.88 TAS2R14 (0.44) MAPTTP53LMNATSHRALDH1A1
SCHEMBL3251014 0.87 TDP1 (0.53) PARGTDP1POLBBRAFMAPT
SCHEMBL3253347 0.87 PARG (0.42) PARGTDP1POLBBRAFMAPT
SCHEMBL3252622 0.86 TDP1 (0.54) PARGTDP1POLBBRAFMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1899335-B1 PYRROLOQUINOLINE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS PF MEDICAMENT (FR) 2010-05-19 EP claimed
US-8426437-B2 Pyrroloquinoline derivatives and their use as protein kinases inhibitors PIERRE FABRE MEDICAMENT (FR) 2013-04-23 US disclosed
US-8426437-B2 Pyrroloquinoline derivatives and their use as protein kinases inhibitors PIERRE FABRE MEDICAMENT (FR) 2013-04-23 US disclosed
US-20090042876-A1 Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors PIERRE FABRE MEDICAMENT (FR) 2009-02-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090042876-A1 Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors MAP3K1, MAP3K2, MAP3K7 PARG 3507/4885TDP1 1098/4885POLB 1007/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.